-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $45

Benzinga·03/25/2026 14:31:32
Listen to the news
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $41 to $45.